<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01505855</url>
  </required_header>
  <id_info>
    <org_study_id>CD vaccination 1.2</org_study_id>
    <nct_id>NCT01505855</nct_id>
  </id_info>
  <brief_title>Efficacy Study of Pneumococcal Vaccination in Crohn's Disease</brief_title>
  <official_title>Serological Response to Pneumococcal Vaccination in Crohn's Disease: A Prospective Multicenter Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Kyunghee University Medical Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Wonju Severance Christian Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Seoul National University Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Asan Medical Center</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Soonchunhyang University Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Ewha Womans University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Kosin University Gospel Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Chung-Ang University Hosptial, Chung-Ang University College of Medicine</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Inje University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>The Catholic University of Korea</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Keimyung University Dongsan Medical Center</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Korea University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Wonkwang University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Severance Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Konkuk University Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Kyunghee University Medical Center</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      A growing number of patients with Crohn's disease are treated with immunosuppressive agents,
      such as anti-tumor necrosis factor blockers and immunomodulators. Several recent studies have
      indicated that immunosuppressive treatment may impair the immunological response to
      pneumococcal vaccination in patients with inflammatory bowel disease (Crohn's disease and
      Ulcerative colitis). One of weaknesses in the previous studies did not focus on specific
      disease, such as Crohn's disease. In addition, predictive factors affecting impaired response
      following pneumococcal vaccination have not clearly evaluated in patients with Crohn's
      disease. In this study, patients with Crohn's disease will be assessed for serological
      response to pneumococcal vaccination. Further, potential predictive factors that impact on
      vaccination outcomes and adverse events related to vaccination will be evaluated.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>December 2011</start_date>
  <completion_date type="Actual">June 2013</completion_date>
  <primary_completion_date type="Actual">June 2013</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Diagnostic</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Serological response rates</measure>
    <time_frame>4 weeks</time_frame>
    <description>Serological response rates, defined by number of patients showing adequate response to pneumococcal vaccination (at least a 2-fold increase in antipneumococcal antibodies in the serum compared with baseline)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Safety assessment of the vaccine</measure>
    <time_frame>8 weeks</time_frame>
    <description>adverse events related to vaccine administration, including worsening of Crohn's disease activity by changes in Harvey-Bradshaw index (HBI) and inflammatory markers</description>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">197</enrollment>
  <condition>Crohn's Disease</condition>
  <arm_group>
    <arm_group_label>anti-TNF only</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Crohn's disease, on an anti-TNF agent [infliximab or adalimumab] only</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Combined immunosuppression</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Crohn's disease, on combined immunosuppression (both anti-TNF agent and immunomodulator [azathioprine or 6-MP])</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Immunomodulator only</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Crohn's disease, on an immunomodulator only</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Non-immunosuppression</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Crohn's disease, not on immunosuppressive medications (5-ASA only: control arm)</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>23-valent polysaccharide pneumococcal vaccine</intervention_name>
    <description>23-valent polysaccharide pneumococcal vaccine (PSV-23 vaccine) 0.5mL single intramuscular injection</description>
    <arm_group_label>anti-TNF only</arm_group_label>
    <arm_group_label>Combined immunosuppression</arm_group_label>
    <arm_group_label>Immunomodulator only</arm_group_label>
    <arm_group_label>Non-immunosuppression</arm_group_label>
    <other_name>Pneumovax</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients over the age of 18

          -  Informed consent

          -  Patients who had a definitive diagnosis of Crohn's disease for more than 6 months
             (documented by the standard clinical, radiographic, endoscopic, and histopathologic
             criteria)

        Exclusion Criteria:

          -  Hypersensitivity to any component of the pneumococcal vaccine

          -  Known allergy to pneumococcal vaccination

          -  Patients who treated with glucocorticoids (prednisolone &gt; 20 mg/day equivalent for 2
             weeks or more, and within 3 months of stopping

          -  Patients who inoculate another vaccine in the past 4 weeks

          -  Significant protein calorie malnutrition

          -  Current signs or symptoms of severe, progressive or uncontrolled renal, hepatic,
             hematologic, endocrine, pulmonary, cardiac, infectious, neurologic or cerebral disease

          -  Any condition which, in the opinion of the Investigator, places the patient at
             unacceptable risk if he/she were to participate in the study
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Hyun-Soo Kim, MD, PhD</last_name>
    <role>Study Chair</role>
    <affiliation>Yonsei University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Yonsei University: Wonju Christian Hospital</name>
      <address>
        <city>Wonju</city>
        <state>Kangwon-do</state>
        <zip>220-701</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kosin University Gospel Hospital</name>
      <address>
        <city>Busan</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Soonchunhyang University</name>
      <address>
        <city>Cheonan</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Keimyung University; Dongsan Hospital</name>
      <address>
        <city>Daegu</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Wonkwang University</name>
      <address>
        <city>Iksan</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kyung Hee University Hospital</name>
      <address>
        <city>Seoul</city>
        <zip>130-702</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Asan Medical Center</name>
      <address>
        <city>Seoul</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Chung-Ang University</name>
      <address>
        <city>Seoul</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ewha Womans University</name>
      <address>
        <city>Seoul</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Inje University; Seoul Paik Hospital</name>
      <address>
        <city>Seoul</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Konkuk University Hospital</name>
      <address>
        <city>Seoul</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Korea University; Ansan Hospital</name>
      <address>
        <city>Seoul</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Yonsei University; Severance Hospital</name>
      <address>
        <city>Seoul</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Seoul National University Hospital</name>
      <address>
        <city>Seul</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The Catholic University of Korea; St. Vincent's Hospital</name>
      <address>
        <city>Suwon</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <reference>
    <citation>Melmed GY, Agarwal N, Frenck RW, Ippoliti AF, Ibanez P, Papadakis KA, Simpson P, Barolet-Garcia C, Ward J, Targan SR, Vasiliauskas EA. Immunosuppression impairs response to pneumococcal polysaccharide vaccination in patients with inflammatory bowel disease. Am J Gastroenterol. 2010 Jan;105(1):148-54. doi: 10.1038/ajg.2009.523. Epub 2009 Sep 15.</citation>
    <PMID>19755964</PMID>
  </reference>
  <reference>
    <citation>Fiorino G, Peyrin-Biroulet L, Naccarato P, Szabò H, Sociale OR, Vetrano S, Fries W, Montanelli A, Repici A, Malesci A, Danese S. Effects of immunosuppression on immune response to pneumococcal vaccine in inflammatory bowel disease: a prospective study. Inflamm Bowel Dis. 2012 Jun;18(6):1042-7. doi: 10.1002/ibd.21800. Epub 2011 Jun 14.</citation>
    <PMID>21674732</PMID>
  </reference>
  <reference>
    <citation>Wasan SK, Coukos JA, Farraye FA. Vaccinating the inflammatory bowel disease patient: deficiencies in gastroenterologists knowledge. Inflamm Bowel Dis. 2011 Dec;17(12):2536-40. doi: 10.1002/ibd.21667. Epub 2011 Apr 28.</citation>
    <PMID>21538710</PMID>
  </reference>
  <verification_date>October 2014</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 2, 2012</study_first_submitted>
  <study_first_submitted_qc>January 4, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 9, 2012</study_first_posted>
  <last_update_submitted>October 14, 2014</last_update_submitted>
  <last_update_submitted_qc>October 14, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">October 16, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Kyunghee University Medical Center</investigator_affiliation>
    <investigator_full_name>Chang Kyun Lee</investigator_full_name>
    <investigator_title>Assistant Professor</investigator_title>
  </responsible_party>
  <keyword>Crohn's disease</keyword>
  <keyword>Pneumococcal vaccination</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Crohn Disease</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Vaccines</mesh_term>
    <mesh_term>Heptavalent Pneumococcal Conjugate Vaccine</mesh_term>
    <mesh_term>Immunologic Factors</mesh_term>
    <mesh_term>Adjuvants, Immunologic</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

